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Abstract—Atherosclerosis, a chronic vascular disease, leads to molecular events bound with interpla-
ying processes of inflammation and coagulation. In the present study, fibronectin (FN), FN containing
extra domain A (EDA-FN), frequency of occurrence, and relative amounts of soluble plasma FN-fibrin
complexes were analyzed in 80 plasma samples of patients suspected of coronary artery disease based on
clinical evaluation and changes in arteries found by computed tomographic coronary angiography. The
study showed that in the plasma of the patients’ group with high risk of coronary artery disease EDA-FN
concentration was significantly higher (3.5 ± 2.5 mg/L; P < 0.025) and the molecular FN-fibrin com-
plexes of 1000 kDa and higher occurred more often than in the groups of patients with mild risk of
coronary artery disease and the normal age-matched. The increased level of EDA-FN and occurrence of
FN-fibrin complexes could have a potential diagnostic value in the diagnosis and management of
patients with coronary artery disease.
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INTRODUCTION
Development of atherosclerotic lesions, which in-
creasingly affect the human population, causing high mor-
bidity and mortality, are known to be associated with
chronic inflammation and can lead to thrombosis and di-
verse cardiovascular diseases [1]. At the cellular and mo-
lecular levels, atherosclerosis is known to activate
immune-inflammatory pathways, encompassing multiple
complex interdependent interactions among inflammatory
cells, vascular elements, extracellular matrix molecules,
and plasma proteins through expression of cytokines, and
several adhesion molecules and their receptors [2–4]. The
atheroprogression is manifested by the development of
atheromatous plaque in the affected vessel wall, which
leads to diverse vascular lesions and disturbs molecular
vessel functions, vascular permeability, and flow of blood
around the body [2, 3, 5].
A key event associated with plaque formation is ex-
pansion and remodeling of extracellular matrix compo-
nents (ECM) in susceptible arterial areas [6].
During atherosclerotic lesions under disease-
dependent conditions, the normal complex organization
of ECM undergoes harmful structural and functional mod-
ifications which can lead to the occurrence of numerous
diseases [6–8]. Among the major proteins of ECM respon-
sible for the organization and regulation of ECM-
dependent molecular functions, a multifunctional and
multidomain glycoprotein, fibronectin (FN), plays a crucial
role [8–10]. FN, besides being an insoluble component of
ECM and tissues (cFN), is also an abundant protein of
plasma and other physiological fluids. In plasma and
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tissues, FN can exist in diverse isoforms arising from
posttranslational modifications (N- and O-glycosylation,
phosphorylation), alternative splicing of FN pre-
messenger RNA (i.e., inclusion of EDA, EDB, and IIICS
segments), and moreover from variable conformations de-
pending on environmental conditions (globular and fibril-
lar structures) [8, 9, 11].
FN is a large dimeric glycoprotein (450–500 kDa);
each monomer of which consists of types I, II, and III of
repeating amino acid units. The multiple copies of repeats
are arranged into several domains able to bind fibrin,
collagen, glycosaminoglycans, and cellular receptors [9,
10]. Two identical or nearly identical (depending on the
included or excluded spliced extra domains) FN polypep-
tides are linked together by two disulfide bonds near their
carboxyl termini. In contrast, their N-termini ends are
unlinked, facilitating formation of many diverse conforma-
tional structures able to react with FN ligands [9, 11]. Its
hepatic origin, plasma form of FN (pFN) lacking extra
EDA and EDB segments, has a looped compact confor-
mation which can be stretched to an unfolded conformation
when FN is caught by cellular integrin receptors [9, 11].
The tissue cellular FN (cFN) is synthesized by many cell
types (e.g., fibroblasts, endothelial cells, platelets, and
monocytes) and bears variable proportions of EDA and
EDB segments (EDA-FN and EDB-FN, respectively) [9,
12].
Both forms, pFN and cFN, are reported to be incor-
porated into the fibrillar network of ECM [9, 10, 13], where
they play structural and functional roles regulating some
cellular activities [9, 14]. The plasma-derived FN is report-
ed to support hemostasis, regulate thrombosis [15, 16], and
significantly accelerate healing, reducing the area of in-
flammation [17, 18]. Plasma FN is also a major component
of the blood clot. With fibrin and its degraded forms, it
readily forms a macromolecular complex which can be
cross-linked covalently in the reaction catalyzed by
transglutaminase XIIIa [16, 19]. Through binding with
fibrin, pFN influences the rate of formation, stability, as
well as the structure of the fibrin matrix [15, 20].
In spite of the fact that both EDA- and EDB-FN
isoforms take part in vasculogenesis in embryos and an-
giogenesis in cancer and non-tumoral conditions, the spe-
cific integrin receptors have been identified exclusively for
EDA-FN [12, 21, 22]. FN carrying the EDA segment
recognized by integrin receptors is reported to be implicat-
ed in efficient adhesion, activation, and aggregation of
platelets, promoting in that way inflammation and coagu-
lation processes [23–25]. The initial step of platelet adhe-
sion is immobilization of dimeric EDA-FN on platelets by
integrins α5β1 and αIIbβ3 and stretching of a dimeric
cFN to its fibrillar form. Maurer et al. [2015] provided
experimental evidence that a fibrillar form of EDA-FN is a
potent thrombogenic component of the subendothelium.
The interaction of immobilized fibrillary EDA-FN to plate-
let integrins together with glycoprotein Ib-V-IX complex, a
major signaling receptor for collagen, and Toll-like recep-
tor 4 initiates molecular reactions which lead to activation
of the coagulation cascade and promotion of thrombus
formation [23]. These events bring a high risk of athero-
sclerosis and thrombosis development [16, 26–28].
On the other hand, EDA-FN located on the top of a
plaque is known to form a protective fibrous cap, which
prevents plaque rupture and vascular occlusion [26, 29–
31].
In the present study, frequency of occurrence and
relative amounts of soluble plasma FN-fibrin complexes
were determined in plasma of patients suspected of coro-
nary artery disease based on significant changes observed
in the patients’ artery. The relative amounts of soluble
plasma FN-fibrin complexes were analyzed with respect
to FN and EDA-FN concentrations, occurrence of FN
monomer, and eventual presence of FN fragments. The
FN and EDA-FN concentrations were estimated by ELISA
with two specific monoclonal antibodies, and the occur-
rence and relative amounts of FN-fibrin complexes and FN
monomer and possible presence of FN degradation prod-
ucts were analyzed by SDS-agarose immunoblotting [32]
andWestern blotting [33], respectively. The study indicates
that the analysis of FN-fibrin complexes and the EDA-FN
concentration can help to better understand the mecha-
nisms underlying thrombosis and changes associated with
endothelial dysfunction and vascular diseases.
MATERIALS AND METHODS
Patients
Patients were included in the study after their clinical
evaluation was performed and informed consent had been
given. The study was approved by the Bioethical Commit-
tee at the Regional Specialist Hospital in Wroclaw and
complies with the 1975 Declaration of Helsinki.
Participants (n = 80, 39 women and 41 men, aged
63.8 ± 9 years) were recruited to the study from persons
attending the Emergency Department of the Regional Spe-
cialized Hospital in Wroclaw because of chest pain and
inconclusive unstable angina pectoris detection by classical
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tests such as high-sensitive troponin I (hsTnI) and electro-
cardiography (ECG).
After hospitalization, the patients suspected of
coronary artery disease (CAD), but with myocardial
infarction excluded, were included in the study based
on standard computed tomographic coronary angiogra-
phy (CTCA) performed as describe previously by
Miszalski-Jamka et al. [34]. CTCA was performed
using a 2×32-slice Dual Source Computed Tomogra-
phy Scanner (Somatom Definition, Siemens, Erlangen,
Germany). Images were reconstructed using a B26f
kernel with an image matrix of 512 × 512 pixels. A
multiphase reconstruction (from 0 to 90 %) was per-
formed and the best quality image reconstructions were
assessed. The post processing and study evaluation
were performed using a dedicated workstation (3D
Leonardo, Syngo Via Siemens Medical Solution, Er-
langen, Germany).
Sampling
Blood samples (4.5 ml), anti-coagulated with 3.2 %
sodium citrate (0.5 ml), were collected from 80 patients
suspected of CAD and plasma was immediately separated
from the blood cells by centrifugation at 2000×g for
10 min. The samples were aliquoted and stored at −76 °C
until analysis.
Eighty patients’ samples were divided into groups 1
and 2 according to the degree of vessel lumen narrowing
caused by arteriosclerotic plaque distinguished based on
the data of computed tomographic coronary angiography
[34]. Group 1 with significant coronary artery changes
comprised 66 plasma samples of patients (30 females and
36 males; mean age 64.4 ± 9 years) with presence of ath-
erosclerotic plaques in the coronary arteries and with one
or more visible stenosis (>50 % vessel lumen narrowing).
Group 2 with mild coronary artery changes comprised 14
blood plasma samples of patients (9 females and 5 males;
mean age 61.5 ± 9 years) with (<50 % vessel lumen
narrowing) or without visible vessel lumen narrowing.
The characteristics of the blood parameters of patients are
summarized in Table 1.
The control group comprised samples taken from
healthy non-smoking volunteers (13 females and 8 males;
mean age 65.3 ± 12 years), members of the WrocławMed-
ical University staff, and 8 people who visited the emer-
gency department because they felt a pain in the chest, but
based on the results of CTCA and normal values of routine
laboratory blood parameters were included in the control
group.
FN Concentration
Plasma FN (pFN, test 1) and EDA-FN (test 2) con-
centrations were determined by two independent ELISAs
using a well-defined domain-specific monoclonal antibody
directed to a centrally located comprehensive cell-binding
domain of FN (FN30-8; M010 TaKaRa Shuzo Co. Ltd.,
Shiga, Japan) [32] or to an extra domain EDA of FN (DH1,
EMD Millipore, Merck KGaA Darmstadt, Germany). The
monoclonal antibodies anti-FN (test 1) and anti-EDA-FN
(test 2), diluted 1:10 000 and 1:3000, respectively, in TBS,
were used as a coating agent in the wells of a microtiter
plate (Nalge Nunc International, Naperville, IL, USA) to
bind FN and EDA-FN in the samples. The amount of FN
bound by the monoclonal antibody was quantified by
rabbit anti-FN polyclonal antibodies (Sigma Chemical
Co, St Louis, MO, USA, diluted 1:5000 (test 1), or
1:2500 (test 2) in TBS containing 0.1 % Tween-20) and
peroxidase-conjugated goat anti-rabbit immunoglobulins
(Sigma Chemical Co, St Louis, MO, USA), diluted
1:20,000 (test 1), or 1:3000 (test 2) as the secondary
antibodies. The amount of FN was assayed by a colorimet-
ric reaction using o-phenylenediamine dihydrochloride/
H2O2 as the enzyme substrate and measured in a Stat Fax
2100Microplate Reader (Awareness Technology Inc, Palm
City, FL, USA) at 450 nmwith 630 nm as a reference filter.
The samples were analyzed in two different sample dilu-
tions, each in duplicate. The pFN and EDA-FN concentra-
tions are given in milligram per liter and presented as the
mean ± standard deviation (SD).
To determine non-specific binding, two controls were
included in the tests: minus primary antibody and minus
secondary antibody.
A human plasma FN preparation (Sigma, St. Louis,
MO, USA, from 2.5 to 50 ng/well) was used as a standard
for FN-ELISA determination (test 1), and acellular fibro-
nectin from human foreskin fibroblasts (Sigma, St. Louis,
MO, USA, from 3.125 to 50 ng/well) for EDA-FN-ELISA
(test 2).
Western Immunoblotting
Plasma samples containing 300 ng of FN were sub-
jected to SDS-(10 %) polyacrylamide gel electrophoresis
under reducing conditions as described earlier [35].
SDS-Agarose FN Immunoblotting
Plasma FN-fibrin complexes were revealed by SDS-
agarose immunoblotting as described previously [32].
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Statistics
Data are presented as means ± standard devia-
tions (SD). Comparisons between groups were per-
formed by means of the Kruskal–Wallis and post hoc
tests. P values less than 0.05 were regarded as
significant.
Receiver operating characteristic (ROC) analysis was
performed with R for Windows (the R Foundation for
Statistical Computing, Vienna, Austria).
To estimate the usefulness of the FN-fibrin complexes
and EDA-FN for differential diagnostics of the state of
patients with significant coronary artery changes compared
to mild coronary artery changes, statistic cluster analysis
was used (Statistica version 12 PL, StatSoft Inc., Tulsa,
OK, USA). The results are presented as a dendrogram,
starting with all the subjects (patients and controls) in one




The mean values of pFN concentration (Fig. 1a)
were similar in patient group 1 with significant coro-
nary artery changes (292.53 ± 74.4 mg/L) and group 2
with mild coronary artery changes (280.21 ± 90.9 mg/
L), but slightly higher than in the control group
(253.38 ± 82.3 mg/L).
EDA-FN Concentration
Compared with the control group (2.0 ± 0.7 mg/L),
the mean EDA-FN concentration (Fig. 1b) was significant-
ly higher in group 1 (3.5 ± 2.5 mg/L; P < 0.025) and at a
similar level in group 2 (2.4 ± 1.9 mg/L).
The ROC curve analysis of EDA-FN concentration
(Fig. 3a) showed a sensitivity of 53 % and specificity of
91 % (area under the curve [AUC] 0.67).
FN Fragments
The electrophoresis of plasma samples in 10 % poly-
acrylamide gel under reducing conditions and subsequent
immunoblotting with anti-FNmonoclonal antibody did not
show the presence of FN fragments.
Occurrence of FN-Fibrin Complexes
SDS-agarose immunoblotting revealed the presence,
beside bands corresponding to FN dimer (500 kDa) and FN
monomer (∼250 kDa), of FN-fibrin bands with decreasing
electrophoretic mobilities (Table 2, Fig. 2) and increasing
molecular masses of 750, 1000, 1300, 1600, 1900, and
2200 kDa. The FN-fibrin bands were numbered as FN-
fibrin complexes I–VI, respectively.






























































































Values of blood parameters are given as mean values ± SD, median, and
(25th and 75th) quartiles. ↑↓ the number of samples with low (↓) or high
(↑) value. All parameters were determined using routine laboratory tech-
niques. All biochemical parameters were determinedwith commercial kits,
and CRP levels were measured with a coagulometer
HDL high-density lipoprotein, LDL low-density lipoprotein, BMI body
mass index, CRP C-reactive protein, hsTnI high-sensitive troponin I
(TnI was measured twice, at the time of admission to an emergency
department and 6 h after)
1062 Lemańska-Perek, Krzyżanowska-Gołąb, Pupek, Klimeczek, Witkiewicz, and Kątnik-Prastowska
The plasmas of group 1 (significant changes in the
coronary artery) contained the set of FN-fibrin complexes
I–VI whose frequency of occurrence (from 0.83 for com-
plex I to 0.03 for complex VI) and their relative amounts
(from 28.3 % for complex I to 4.4 % for complex VI)
decreased with the increased molecular mass of the FN-
fibrin complexes. In contrast, the plasma of group 2 (mild
coronary artery changes) and age-matched controls, beside
the FN-fibrin complex I occurring in about 70 % of sam-
ples, contained none of the detectable FN-fibrin complexes
II–VI, excluding one sample of group 2, which revealed
the presence of complex II. Moreover, the mean relative
amount of FN-fibrin complex I (13.36 ± 10.2 %) was
higher in group 1 than in group 2 (7.25 ± 6.7 %) and the
control group (6.88 ± 4.6 %).
ROC curve analysis of the relative amounts of FN-
fibrin complexes (∼750 and ∼1000 kDa) identified param-
eters with a sensitivity of 53 % and specificity of 88 %
(AUC 0.67) for complex I (Fig. 3b) and a sensitivity of
39 % and specificity of 97 % (AUC 0.68) for complex II
(Fig. 3c).
Cluster analysis (Fig. 4) based on the relative amounts
of FN-fibrin complexes and EDA-FN concentration data of
groups 1, 2, and the age-matched group allowed the cluster
A samples (n = 21, 32 %) from group 1 to be separated
from the rest of the samples (cluster B).
The analysis for atherosclerosis risk factors (total
cholesterol, LDL, HDL, BMI, CRP, glucose level, sex,
and age) showed that the samples from cluster A have
slightly higher levels of HDL and LDL (62.2 ± 50.4
and 130.6 ± 45.9, respectively) compared to the rest of
the patients from the group of significant coronary
artery changes (56.1 ± 33.8 and 117.8 ± 44.4, respec-
tively). Moreover, the patients in this subgroup were
significantly younger (mean age 60.4 ± 8 years,
P < 0.022) than the rest of patients in this group (mean
age 66 ± 9 years).
DISCUSSION
The study showed that the presence of soluble FN-
fibrin complexes and high concentration of the FN isoform
bearing an EDA segment (EDA-FN) in patients’ plasma
were associated with significant changes in the coronary
artery, and these subjects were suspected of high risk of
coronary artery disease (CAD) more often than in those
with mild or no changes in blood vessels.
The high EDA-FN concentration (Fig. 2b) in the
plasma samples of patients with high risk of CAD com-
pared with its low level in the plasma of controls as well as
patients with low risk of CAD (Fig. 2b) has also been
observed by others in ischemic stroke [36], diabetes [37],
atherosclerosis [30], and cancer [38]. EDA-FN occurrence
in plasma at a high concentration is believed to be associ-
ated with inflammation and its release from tissues to the
circulation during arterial wall lesions in thrombosis [39],
plaque formation, development and progression of
Fig. 1. Distribution of FN (a) and EDA-FN (b) concentrations in plasma of patients with atherosclerosis. pFN (a) and EDA-FN (b) concentrations were
determined by ELISA [35], using two monoclonal antibodies domain-specific directed to cell-binding domain of FN (FN30-8; M010 TaKaRa Shuzo Co.
Ltd., Shiga, Japan) and EDA segment of FN (EMDMillipore, Merck KGaA Darmstadt, Germany). For details see “Materials and Methods.” Data are given
as mean values ± SD, median, and (25th and 75th) quartiles. Significantly different from the age-matched normal group calculated by the Kruskal–Wallis and
post hoc tests.
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atherosclerosis, and arterial aging [24, 26–28]. However,
the high EDA level in plasma can also reflect other path-
ophysiological processes connected with reconstruction of
ECM [37] which can mask the changes due to atheroscle-
rosis [30]. On the other hand, pFN (lacking an EDA
segment) level in the plasma samples of patients with high
and low risk of CAD did not differ from that in the normal
group (Fig. 1a), and its diagnostic usefulness has been
reported to be controversial, being probably due to differ-
ent exclusion criteria for patients and differential timing of
FN measurements in relationships to disease [16].
The present work also revealed the presence of FN-
fibrin complexes of 750, 1000, 1300, and 1600 kDa in
some plasma samples of patients with a high risk of CAD
(Table 2, Fig. 2), which were absent in the plasma of age-
matched patients and those with a low risk of CAD, though
with the exception of the presence of the complex with the
smallest molecular mass of 750 kDa. The presence of the
set of the FN-fibrin complexes has been previously report-
ed by our group for plasma of patients with some inflam-
matory diseases [32, 40]. In contrast, none of them were
found in plasma of young and middle aged healthy indi-
viduals, but the 750-kDa complex occurred progressively
with aging of individuals [32, 33, 41].
The occurrence of FN-fibrin complexes in plasma of
patients seems to reflect molecular events connected with
interplaying processes of inflammation, immunity, and co-
agulation (Fig. 5).When the coagulation process is activated
by inflammatory agent/s, the plasma fibrinogen is converted
to fibrin, which in contrast to untouched fibrinogen is able to
form a complex with pFN. The fibrils of FN-fibrin are
rapidly deposited in the injured vessel wall as the first factor
in the wave of hemostasis and clot formation. The cascade
of reactions of the coagulation system is under control and
the thrombus is dissolved by the fibrinolytic system. In
consequence, the lesion in the blood vessel is repaired by
the wound healing process [9]. However, any imbalance/
dysregulation between procoagulant/antifibrinolytic and an-
ticoagulant factors may lead to hypercoagulation, destruc-
tion of vessels, thrombosis, and atherosclerosis (Fig. 3).
Such a situation may happen in disease-dependent condi-
tions and with aging [44].
Table 2. Frequency of Occurrence and Relative Amount of Fn-Fibrin Complexes in Plasma of Patients with Atherosclerosis
Plasma FN forms Mm (kDa) Frequency of occurrence and relative amount of FN forms
in plasma groups 1–3
Mean value of relative amount ± SD
1. Significant coronary
artery changes n = 66
2. Mild coronary artery
changes n = 14
3. Age-matched normal
group n = 21































































Plasma FN forms were revealed by SDS-agarose immunoblotting (see Fig. 2). Frequency of occurrence is the ratio of the number of samples containing the
FN form to the total number of samples. In parentheses are given the number of samples which revealed the respective FN band. The relative amount of the
FN band is the percentage of the total number of pixels found in the electrophoresis path and is expressed as mean value ± SD. Data are presented as mean
values ± SD. Significantly different from the age-matched normal group calculated by the Kruskal–Wallis and post hoc tests
aThe relative amount for the sample from group 2 with mild coronary artery changes (∼1000 kDa)
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The FN-fibrin complexes are reported to play a dif-
ferent biological role than unbound pFN [15]. The pFN-
fibrin complex supports platelet aggregation and thrombo-
sis and has prothrombotic activities [15, 42]. Moreover,
Wang et al. (2014) reported that pFN through interactions
with fibrin is able to switch from supporting hemostasis to
inhibiting thrombosis/vessel occlusion, depending on the
gradient of fibrin, and indicate that fibronectin is a self-
limiting regulator in thrombosis [15].
Interestingly, the relative amounts of the FN-fibrin
complexes did not show any correlation with the plasma
EDA-FN concentration. The high concentration of EDA-
FN probably reflects progression of the atherogenic lesion,
whereas the presence of FN-fibrin complexes in high
amounts contributes to the hypercoagulation state (Fig. 5),
although to a variable degree. The profile of FN-fibrin
macro-complexes composed of the ladder of bands with
Fig. 2. Representative immunopatterns of FN-fibrin complexes in plasma
samples of patients with atherosclerosis and age-matched normal group.
The 101 blood plasma samples of atherosclerotic patients and age-matched
normal individuals were subjected to SDS-agarose immunoblotting under
non-reducing conditions [32]. For details see “Materials and Methods.”
Plasma samples: lanes 1–2, significant coronary artery changes; lane 3,
mild coronary artery changes; lanes 4–5, normal age-matched plasma. The
molecular masses of the 750 to 2200 kDa plasma FN-fibrin complexes and
500 kDa FN dimer are shown by arrows on the left.
Fig. 3. ROC curves for values of EDA-FN concentration (a) and FN-fibrin complexes I (b) and II (c) relative amounts in plasma of patients with
atherosclerosis. Data are given as AUC with 95 % confidence interval.
Fig. 4. Dendrogram of cluster analysis based on the data of FN-fibrin
complexes and EDA-FN levels of human blood plasma samples of ath-
erosclerotic patients and age-matched normal individuals. Triple asterisks
indicate significant coronary artery changes, double asterisks mild coro-
nary artery changes, and asterisk normal age-matched plasma. Cluster A
and cut-off lane governing patients with significant coronary artery chang-
es from the rest of samples with significant or mild coronary artery changes
and controls (cluster B).
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molecular masses higher than 1000 kDa, not observed in
the normal plasma or in the samples of patients with mild
coronary artery changes, but evidently revealed in the
plasma of patients with significant coronary artery changes
(Table 2), might be related to increased coagulation. The
patients whose plasma revealed such a pattern of FN-fibrin
complexes might be suspected of hypercoagulability and
high risk of thrombosis, and they should be under special
medical care. However, it could not be excluded that the
presence of high-molecular FN-fibrin complexes might be
bound additionally with severity of coexisting diseases.
For example, we have observed the presence of the FN-
fibrin complexes with molecular masses up to 1900 kDa in
the plasma samples of patients with significant coronary
artery changes and with acute chest pain, but without
medical evidence of acute myocardial infarction. The clus-
ter analysis based on the data of FN-fibrin complexes and
EDA-FN levels (Fig. 4) allowed us to separate the sub-
group of patients with significant coronary artery changes
who should be under special medical care because of high
risk of hypercoagulation and thrombosis.
To conclude, the profile analysis of FN-fibrin com-
plexes and the determination of EDA-FN concentration,
but not plasma FN in the plasma of patients, could be
considered as a potential diagnostic biomarker helpful in
diagnosis, management, and prophylaxis of patients with
high risk of atherosclerosis and moreover may help to
discriminate the group of patients with high risk of CAD
from that with mild risk of CAD.
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